Comparison · NCT06680206-df774e3d
Rimegepant vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rimegepant vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis. Trial comparisons, record NCT06680206-df774e3d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06680206-df774e3d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.533 | 0.449 | 0.615 | wilson | |
| Risk in group 2 | 0.297 | 0.272 | 0.323 | wilson | |
| Risk difference, group 1 minus group 2 | 0.237 | 0.149 | 0.322 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.8 | 1.5 | 2.15 | log | |
| Odds ratio, group 1 over group 2 | 2.71 | 1.89 | 3.88 | log | |
| Number needed to treat, for one more participant with the outcome on Rimegepant than on Triptans | 4.23 | 3.1 | 6.72 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rimegepant | Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study. | 72 | 135 | OG000 |
| Group 2 | Triptans | Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study. | 374 | 1,260 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis
- Description
- Analysis was performed using IPTW method to adjust for confounding by the covariates.
- Time frame
- 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 month of this observational study.
- Population
Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
- NCT number
- NCT06680206
- Phases
- Conditions
- Migraine
- Interventions
- Rimegepant, Triptans
- Lead sponsor
- Pfizer
- Results first posted
- 2026-01-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06680206?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06680206-df774e3d